|
1
|
Eriksson M, Stecksén A, Glader EL,
Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A and
Asplund K: Riks-Stroke Collaboration. Discarding heparins as
treatment for progressive stroke in Sweden 2001 to 2008. Stroke.
41:2552–2558. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Birschel P, Ellul J and Barer D:
Progressing stroke: Towards an internationally agreed definition.
Cerebrovasc Dis. 17:242–252. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Helleberg BH, Ellekjaer H and Indredavik
B: Outcomes after early neurological deterioration and transitory
deterioration in acute ischemic stroke patients. Cerebrovasc Dis.
42:378–386. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Weimar C, Mieck T, Buchthal J, Ehrenfeld
CE, Schmid E and Diener HC: German Stroke Study Collaboration.
Neurologic worsening during the acute phase of ischemic stroke.
Arch Neurol. 62:393–397. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kwan J and Hand P: Early neurological
deterioration in acute stroke: Clinical characteristics and impact
on outcome. QJM. 99:625–633. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Seners P and Baron JC: Revisiting
‹progressive stroke›: Incidence, predictors, pathophysiology, and
management of unexplained early neurological deterioration
following acute ischemic stroke. J Neurol. 265:216–225.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Caplan LR: Treatment of ‘progressive’
stroke. Stroke. 22:694–695. 1991.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schwarz M, Meade G, Stoll P, Ylanne J,
Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, et
al: Conformation-specific blockade of the integrin GPIIb/IIIa: A
novel antiplatelet strategy that selectively targets activated
platelets. Circ Res. 99:25–33. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Casserly IP and Topol EJ: Glycoprotein
IIb/IIIa antagonists-from bench to practice. Cell Mol Life Sci.
59:478–500. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Adams HP Jr, Effron MB, Torner J, Dávalos
A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES,
et al: Emergency administration of abciximab for treatment of
patients with acute ischemic stroke: Results of an international
phase III trial: Abciximab in Emergency Treatment of Stroke Trial
(AbESTT-II). Stroke. 39:87–99. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Puri A, Bansal A, Narain VS, Sethi R,
Dwivedi SK, Puri VK and Saran RK: Comparative assessment of
platelet GpIIb/IIIa receptor occupancy ratio with
Eptifibatide/Tirofiban in patients presenting with ACS and
undergoing PCI. Indian Heart J. 65:152–157. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhou X, Wu X, Sun H and Li J: Efficacy and
safety of eptifibatide versus tirofiban in acute coronary syndrome
patients: A systematic review and meta-analysis. J Evid Based Med.
10:136–144. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang M, Huo X, Miao Z and Wang Y: Platelet
glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute
ischemic stroke. Drugs. 79:515–529. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Martin-Schild S, Shaltoni H, Abraham AT,
Barreto AD, Hallevi H, Gonzales NR, Grotta JC and Savitz SI: Safety
of eptifibatide for subcortical stroke progression. Cerebrovasc
Dis. 28:595–600. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Philipps J, Thomalla G, Glahn J, Schwarze
M and Rother J: Treatment of progressive stroke with
tirofiban-experience in 35 patients. Cerebrovasc Dis. 28:435–438.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Peng B and Wu B: Guidelines for the
diagnosis and treatment of acute ischemic stroke in China 2018.
Chin J Neurol. 51:666–682. 2018.
|
|
17
|
Wang Y, Wang Y, Zhao X, Liu L, Wang D,
Wang C, Wang C, Li H, Meng X, Cui L, et al: Clopidogrel with
aspirin in acute minor stroke or transient ischemic attack. N Engl
J Med. 369:11–19. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Derdeyn CP, Chimowitz MI, Lynn MJ,
Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF,
Lutsep HL, et al: Aggressive medical treatment with or without
stenting in high-risk patients with intracranial artery stenosis
(SAMMPRIS): The final results of a randomised trial. Lancet.
383:333–341. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan
TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters
MF, et al: Stenting versus aggressive medical therapy for
intracranial arterial stenosis. N Engl J Med. 365:993–1003.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Adams HP Jr, Bendixen BH, Kappelle LJ,
Biller J, Love BB, Gordon DL and Marsh EE III: Classification of
subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial. TOAST. Trial of Org 10172 in acute
stroke treatment. Stroke. 24:35–41. 1993.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kirmani JF, Korya D, Choi G, Brar J,
Chahal H, Hussain M, Mehta S, Panezai S and Moussavi M: Abstract T
P3: Safety of eptifibatide after full dose IV tPA and endovascular
treatment for ischemic stroke. Stroke. 46 (suppl_1)(ATP3)2015.
|
|
22
|
Ma G, Sun X, Cheng H, Burgin WS, Luo W,
Jia W, Liu Y, He W, Geng X, Zhu L, et al: Combined approach to
eptifibatide and thrombectomy in acute ischemic stroke because of
large vessel occlusion: A matched-control analysis. Stroke.
53:1580–1588. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim SK, Song P, Hong JM, Pak CY, Chung CS,
Lee KH and Kim GM: Prediction of progressive motor deficits in
patients with deep subcortical infarction. Cerebrovasc Dis.
25:297–303. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Steinke W and Ley SC: Lacunar stroke is
the major cause of progressive motor deficits. Stroke.
33:1510–1516. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Donnan GA, O'Malley HM, Quang L, Hurley S
and Bladin PF: The capsular warning syndrome: Pathogenesis and
clinical features. Neurology. 43:957–962. 1993.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Foschi M, Pavolucci L, Rondelli F, Barone
V, Rinaldi R, Spinardi L, Favaretto E, Rucci P, Giostra F, Cosmi B,
et al: Capsular warning syndrome: Features, risk profile, and
prognosis in a large prospective TIA cohort. Cerebrovasc Dis: Sep
9, 2022 (Epub ahead of print).
|
|
27
|
Li W, Wu Y, Li XS, Liu CC, Huang SH, Liang
CR, Wang H, Zhang LL, Xu ZQ, Wang YJ and Zhang M: Intravenous
tirofiban therapy for patients with capsular warning syndrome.
Stroke Vasc Neurol. 4:22–27. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lin L, Li W, Liu CC, Wu Y, Huang SH, Li
XS, Liang CR, Wang H, Zhang LL, Xu ZQ, et al: Safety and
preliminary efficacy of intravenous tirofiban in acute ischemic
stroke patient without arterial occlusion on neurovascular imaging
studies. J Neurol Sci. 383:175–179. 2017.PubMed/NCBI View Article : Google Scholar
|
